VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma Acute Myeloid Leukemia or T-cell Lymphoma

  • STATUS
    Recruiting
  • days left to enroll
    25
  • participants needed
    65
  • sponsor
    Mayo Clinic
Updated on 7 October 2021
ct scan
cancer
stem cell transplantation
myeloid leukemia
cyclophosphamide
lymphoma
multiple myeloma
monoclonal antibodies
measurable disease
direct bilirubin
leukemia
acute promyelocytic leukemia
neutrophil count
tumor cells
monoclonal antibody therapy
monoclonal protein
biological therapy
line of therapy
immunoglobulin
electrophoresis
alkylating agent
t-cell lymphoma
mycosis fungoides
alkylating agents
refractory multiple myeloma
immunomodulatory imide drug
cutaneous t-cell lymphoma
vsv-hifnbeta-nis

Summary

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without ruxolitinib phosphate in treating patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS and ruxolitinib phosphate may work better at treating multiple myeloma, acute myeloid leukemia and T-cell lymphoma.

Description

PRIMARY OBJECTIVE:

I. To determine the maximum tolerated dose (MTD) of VSV-hIFNbeta-NIS in different treatment regimens (alone [group A] and in combination with ruxolitinib phosphate [ruxolitinib] [group B]) in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma and in combination with ruxolitinib and cyclophosphamide (group C) in relapsed/refractory multiple myeloma patients.

SECONDARY OBJECTIVES:

I. To determine the safety profile of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib).

II. To estimate clinical response rate of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib) in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma overall and by disease type.

III. To estimate progression-free and overall survival of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib) in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma overall and by disease type.

CORRELATIVE OBJECTIVES:

I. To determine the time course of viral gene expression and virus elimination, and the biodistribution of virally infected cells at various times points after infection with VSV-hIFNbeta-NIS using planar and single photon emission computed tomography (SPECT)/computed tomography (CT) imaging.

II. To assess virus replication, viremia, viral shedding in urine and respiratory secretions, and virus persistence after systemic administration of VSV-hIFNbeta-NIS.

III. To characterize the pharmacodynamics (PD) of VSV-IFNbeta-NIS by way of measuring serum interferon-beta and also vesicular stomatitis virus (VSV)-real time (RT)-polymerase chain reaction (PCR) of VSV-IFNbeta-NIS.

IV. Assess CD8+ T cell (both general and VSV-IFNbeta-NIS specific) and natural killer (NK) cell responses.

V. Gene expression analysis pre- and post-virotherapy. VI. Assess presence of VSV in tumor and normal tissues subsequent to administration of intravenous (IV) VSV-IFNbeta-NIS.

VII. To identify the best dose of VSV-hIFNbeta-NIS in the regimen being evaluated based on activity observed in the correlative measures described above in those dose levels identified as tolerable.

OUTLINE: This is a dose escalation study of VSV-IFNbeta-NIS. Patients are assigned to 1 of 3 groups.

GROUP A: Patients receive VSV-IFNbeta-NIS intravenously (IV) over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.

GROUP B: Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate orally (PO) twice daily (BID) on days -1 to 9. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.

GROUP C: Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days -1 to 9. Patients also receive cyclophosphamide IV over 2 hours on day 2. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.

After completion of study treatment, patients are followed up for 28 days, and then every 3 months for up to 1 year or until progressive disease, then every 6 months for 1 year.

Details
Condition Bone marrow disorder, Preleukemia, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Recurrent Adult Acute Myeloid Leukemia, Refractory Multiple Myeloma, Refractory Anaplastic Large Cell Lymphoma, Previously Treated Myelodysplastic Syndrome, Recurrent Anaplastic Large Cell Lymphoma, Refractory Acute Myeloid Leukemia, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, myelodysplastic syndromes, myelodysplastic syndrome (mds), refractory acute myeloid leukemia (aml), Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Treatment cyclophosphamide, laboratory biomarker analysis, computed tomography, Biological Therapy, pharmacological study, single photon emission computed tomography, Ruxolitinib Phosphate, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Clinical Study IdentifierNCT03017820
SponsorMayo Clinic
Last Modified on7 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Relapsed or refractory
Groups A, B, or C: Multiple myeloma (MM) previously treated with an immunomodulatory drug (IMID), a proteosome inhibitor and an alkylating agent; OR
Groups A or B: Acute myeloid leukemia (AML), excluding acute promyelocytic leukemia (PML-RARA rearranged- AML-M3); either primary refractory or relapsed/refractory disease after at least two front line chemotherapy regimens (note: induction and consolidation chemotherapy is considered one line of therapy); diagnosis based on 2008 World Health Organization (WHO) criteria; OR
Groups A, B, or C: Relapsed T-cell lymphoma (TCL) or the following types: peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell (ALCL), and cutaneous TCL (CTCL) of mycosis fungoides (MF); patients should have failed standard therapy and in the case of PTCL-NOS, AITL, and ALCL either have failed or be ineligible for high-dose therapy with autologous stem cell transplant
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN) (obtained =< 14 days prior to registration)
Creatinine =< 2.0 mg/dL (obtained =< 14 days prior to registration)
Direct bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)
International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 14 days prior to registration)
If baseline liver disease, Child Pugh score not exceeding class A (obtained =< 14 days prior to registration)
Negative pregnancy test for persons of child-bearing potential (obtained =< 14 days prior to registration)
FOR MULTIPLE MYELOMA ONLY: Measurable disease of multiple myeloma as defined by at least ONE of the following
Serum monoclonal protein >= 1.0 g/dL by protein electrophoresis
>= 200 mg of monoclonal protein in the urine on 24-hour electrophoresis
Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
FOR MULTIPLE MYELOMA ONLY: Absolute neutrophil count (ANC) >= 1000/uL (obtained =< 14 days prior to registration)
FOR MULTIPLE MYELOMA ONLY: Platelet (PLT) >= 100,000/uL (obtained =< 14 days prior to registration)
FOR MULTIPLE MYELOMA ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)
FOR AML ONLY: No ANC restriction (obtained =< 14 days prior to registration)
FOR AML ONLY: PLT >= 10,000/uL (transfusion to get platelets >= 10,000 is allowed) (obtained =< 14 days prior to registration)
FOR AML ONLY: Hemoglobin >= 7.5 g/dl (obtained =< 14 days prior to registration)
FOR AML ONLY: Absence of uncompensated disseminated intravascular coagulation (DIC- as diagnosed by standard International Society on Thrombosis and Hemostasis [ISTH] criteria)
FOR TCL ONLY: ANC >= 1,000/uL (obtained =< 14 days prior to registration)
FOR TCL ONLY: PLT >= 100,000/uL (obtained =< 14 days prior to registration)
FOR TCL ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)
FOR TCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood > 5 x 10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record
Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory
Ability to provide written informed consent
Willingness to return to Mayo Clinic for follow-up
Life expectancy >= 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
Willing to provide mandatory biological specimens for research purposes

Exclusion Criteria

Availability of and patient acceptance of curative therapy
Uncontrolled infection
Active tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis
Any of the following prior therapies
Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =< 2 weeks prior to registration
Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration
Experimental agent in case of AML or TCL within 4 half-lives of the last dose of the agent
New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])
Active CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology; in case of AML active CNS involvement as detected by lumbar puncture or neuro-imaging (only to be done if clinically indicated)
Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression
Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation)
NOTE: in AML, the concurrent use of hydroxyurea to help control proliferative counts is allowed throughout the treatment protocol
NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritis and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are
unknown
Pregnant women or women of reproductive ability who are unwilling to use effective contraception
Nursing women
Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment
AML ONLY: Current disseminated intravascular coagulopathy (DIC)
Prior allogeneic bone marrow transplant
ADDITION EXCLUSION CRITERIA FOR GROUP A (LOW TUMOR BURDEN) ONLY
AML ONLY: Acute promyelocytic leukemia (PML-RARA rearranged- AML-M3)
AML ONLY: AML with > 30% circulating blasts and > 50% bone marrow blasts
MULTIPLE MYELOMA ONLY: Multiple : >= 15% plasmas cells or plasmacytoma > 5 cm in largest diameter
TCL ONLY: Any mass >= 5 cm
ADDITIONAL EXCLUSION CRITERIA FOR GROUP C (COMBINATION WITH CYCLOPHOSPHAMIDE) ONLY
Diagnosis of AML
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note